Ziv-aflibercept

In one trial, 1,226 patients were randomly assigned to receive ziv-aflibercept (4 mg/kg intravenously) or placebo every 2 weeks in combination with FOLFIRI.[39][Level of evidence A2]

In one trial, 1,226 patients were randomly assigned to receive ziv-aflibercept (4 mg/kg intravenously) or placebo every 2 weeks in combination with FOLFIRI.[39][Level of evidence A2]

Patients who received ziv-aflibercept plus FOLFIRI had significantly improved OS rates, with median survival times of 13.50 months compared with patients who received placebo plus FOLFIRI, with median survival times of 12.06 months (HR, 0.817; 95.34% CI, 0.713–0.937; P = .0032).

In one trial, 1,226 patients were randomly assigned to receive ziv-aflibercept (4 mg/kg intravenously) or placebo every 2 weeks in combination with FOLFIRI.[39][Level of evidence A2]

Patients who received ziv-aflibercept plus FOLFIRI also had significantly improved PFS rates, with median PFS rates of 6.90 months compared with patients who received placebo plus FOLFIRI, with median PFS rates of 4.67 months (HR, 0.758; 95% CI, 0.661–0.869; P < .0001).

In one trial, 1,226 patients were randomly assigned to receive ziv-aflibercept (4 mg/kg intravenously) or placebo every 2 weeks in combination with FOLFIRI.[39][Level of evidence A2]

Based on these results, the use of FOLFIRI plus ziv-aflibercept is an acceptable second-line regimen for patients previously treated with FOLFOX-based chemotherapy. Whether to continue bevacizumab or initiate ziv-aflibercept in second-line therapy has not been addressed as yet in any clinical trial, and there are no data available.